Urinary Potassium Excretion, Fibroblast Growth Factor 23, and Incident Hypertension in the General Population-Based PREVEND Cohort
- PMID: 34960084
- PMCID: PMC8707837
- DOI: 10.3390/nu13124532
Urinary Potassium Excretion, Fibroblast Growth Factor 23, and Incident Hypertension in the General Population-Based PREVEND Cohort
Abstract
High plasma fibroblast growth factor 23 (FGF23) and low potassium intake have each been associated with incident hypertension. We recently demonstrated that potassium supplementation reduces FGF23 levels in pre-hypertensive individuals. The aim of the current study was to address whether 24-h urinary potassium excretion, reflecting dietary potassium intake, is associated with FGF23, and whether FGF23 mediates the association between urinary potassium excretion and incident hypertension in the general population. At baseline, 4194 community-dwelling individuals without hypertension were included. Mean urinary potassium excretion was 76 (23) mmol/24 h in men, and 64 (20) mmol/24 h in women. Plasma C-terminal FGF23 was 64.5 (54.2-77.8) RU/mL in men, and 70.3 (56.5-89.5) RU/mL in women. Urinary potassium excretion was inversely associated with FGF23, independent of age, sex, urinary sodium excretion, bone and mineral parameters, inflammation, and iron status (St. β -0.02, p < 0.05). The lowest sex-specific urinary potassium excretion tertile (HR 1.18 (95% CI 1.01-1.37)), and the highest sex-specific tertile of FGF23 (HR 1.17 (95% CI 1.01-1.37)) were each associated with incident hypertension, compared with the reference tertile. FGF23 did not mediate the association between urinary potassium excretion and incident hypertension. Increasing potassium intake, and reducing plasma FGF23 could be independent targets to reduce the risk of hypertension in the general population.
Keywords: FGF23; diet; epidemiology; hypertension; potassium.
Conflict of interest statement
The authors have no conflict of interest to declare.
Figures


Similar articles
-
Urinary potassium excretion and risk of developing hypertension: the prevention of renal and vascular end-stage disease study.Hypertension. 2014 Oct;64(4):769-76. doi: 10.1161/HYPERTENSIONAHA.114.03750. Epub 2014 Jul 21. Hypertension. 2014. PMID: 25047575
-
Urinary tetrahydroaldosterone is associated with circulating FGF23 in kidney stone formers.Urolithiasis. 2022 Jun;50(3):333-340. doi: 10.1007/s00240-022-01317-2. Epub 2022 Feb 24. Urolithiasis. 2022. PMID: 35201364 Free PMC article.
-
Urinary potassium excretion, renal ammoniagenesis, and risk of graft failure and mortality in renal transplant recipients.Am J Clin Nutr. 2016 Dec;104(6):1703-1711. doi: 10.3945/ajcn.116.134056. Epub 2016 Nov 9. Am J Clin Nutr. 2016. PMID: 27935524
-
Sodium and potassium and the pathogenesis of hypertension.Curr Hypertens Rep. 2013 Apr;15(2):122-30. doi: 10.1007/s11906-013-0331-x. Curr Hypertens Rep. 2013. PMID: 23397214 Review.
-
Upstream Regulators of Fibroblast Growth Factor 23.Front Endocrinol (Lausanne). 2021 Feb 26;12:588096. doi: 10.3389/fendo.2021.588096. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33716961 Free PMC article. Review.
Cited by
-
High Intake of Sodium Chloride for 28 Days Causes No Effect on Serum FGF23 Concentrations in Cats.Animals (Basel). 2022 Nov 18;12(22):3195. doi: 10.3390/ani12223195. Animals (Basel). 2022. PMID: 36428422 Free PMC article.
References
-
- NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–980. doi: 10.1016/S0140-6736(21)01330-1. - DOI - PMC - PubMed
-
- WHO . Guideline: Potassium Intake for Adults and Children. World Health Organization; Geneva, Switzerland: 2012. - PubMed
-
- Kieneker L.M., Gansevoort R.T., Mukamal K.J., De Boer R.A., Navis G., Bakker S.J.L., Joosten M.M. Urinary potassium excretion and risk of developing hypertension: The prevention of renal and vascular end-stage disease study. Hypertension. 2014;64:769–776. doi: 10.1161/HYPERTENSIONAHA.114.03750. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical